When was OS Therapies founded?

OS Therapies was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is OS Therapies located?

OS Therapies is headquartered in Cambridge, United States.

How many employees does OS Therapies have?

As of Aug 31, 2026, the latest employee count at OS Therapies is 11.

Is OS Therapies a funded company?

OS Therapies is a funded company, having raised a total of $8.36M across 10 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 25, 2018.

When was the latest funding round of OS Therapies?

OS Therapies' latest funding was a $***** Post IPO round on Jun 30, 2026, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.48B in funding in 2026 to date.

Where does OS Therapies rank among its competitors?

OS Therapies ranks 560th amongst 3394 active competitors, of which 1130 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of OS Therapies?

OS Therapies' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

OS Therapies - 2026 Company Profile, Team, Funding & Competitors

OS Therapies is a public company based in Cambridge (United States), founded in 2017. It operates as a Developer of therapies for treating cancer. OS Therapies has raised $8.36M in funding. The company has 3394 active competitors, including 1130 funded and 783 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapies for treating cancer. The lead candidate of the company acts on HER-2 a member of the human epidermal growth factor receptor such as HER/EGFR/ERB which is used to treat Osteosarcoma. Also, developing folate receptor-targeted TDC for ovarian, pancreatic, lung, and others.

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Public

Total Funding

$8.36M in 10 rounds

Latest Funding Round

Post IPO, Jun 30, 2026, $*****

Investors

K20 Fund

Ranked

560^th among 3394 active competitors

Employee Count

11 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3017 more

Exit Details

Public

View OS Therapies' full profile

OS Therapies got listed on Aug 01, 2024.

Click here to take a look at OS Therapies's IPO in detail

OS Therapies has raised a total funding of $8.36M over 10 rounds. Its first funding round was on Jul 25, 2018. OS Therapies has 1 institutional investor.

Here is the list of recent funding rounds of OS Therapies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 30, 2026	2658075	Post IPO	5290556	7089828	7971513	5027411
Mar 04, 2026	5511834	Post IPO	5478907	6711966	8263515	3949323
Jan 14, 2026	3557047	Post IPO	3414177	9261408	2119799	3478862

Access funding benchmarks and valuations. Sign up today!

View details of OS Therapies's funding rounds and investors

OS Therapies' employee count trend

OS Therapies has 11 employees as of Aug 26. Here is OS Therapies's employee count trend over the years:

Uncover OS Therapies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OS Therapies include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of OS Therapies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
560th	OS Therapies 2017, Cambridge (United States), Public	Developer of therapies for treating cancer	$8.36M	K20 Fund	51/100